345 related articles for article (PubMed ID: 11132236)
1. Iron overload and iron-chelating therapy in hemoglobin E-beta thalassemia.
Olivieri NF; De Silva S; Premawardena A; Sharma S; Viens AM; Taylor CM; Brittenham GM; Weatherall DJ
J Pediatr Hematol Oncol; 2000; 22(6):593-7. PubMed ID: 11132236
[TBL] [Abstract][Full Text] [Related]
2. Challenges in chronic transfusion for patients with thalassemia.
Lal A
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):160-166. PubMed ID: 33275743
[TBL] [Abstract][Full Text] [Related]
3. Role of vitamin C as an adjuvant therapy to different iron chelators in young β-thalassemia major patients: efficacy and safety in relation to tissue iron overload.
Elalfy MS; Saber MM; Adly AA; Ismail EA; Tarif M; Ibrahim F; Elalfy OM
Eur J Haematol; 2016 Mar; 96(3):318-26. PubMed ID: 26018112
[TBL] [Abstract][Full Text] [Related]
4. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.
Marsella M; Borgna-Pignatti C
Hematol Oncol Clin North Am; 2014 Aug; 28(4):703-27, vi. PubMed ID: 25064709
[TBL] [Abstract][Full Text] [Related]
5. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
6. Iron overload in β-thalassemia intermedia: an emerging concern.
Musallam KM; Cappellini MD; Taher AT
Curr Opin Hematol; 2013 May; 20(3):187-92. PubMed ID: 23426199
[TBL] [Abstract][Full Text] [Related]
7. New therapeutic targets in transfusion-dependent and -independent thalassemia.
Cappellini MD; Motta I
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):278-283. PubMed ID: 29222267
[TBL] [Abstract][Full Text] [Related]
8. Liver iron concentrations and urinary hepcidin in beta-thalassemia.
Origa R; Galanello R; Ganz T; Giagu N; Maccioni L; Faa G; Nemeth E
Haematologica; 2007 May; 92(5):583-8. PubMed ID: 17488680
[TBL] [Abstract][Full Text] [Related]
9. Thalassemia.
Cohen AR; Galanello R; Pennell DJ; Cunningham MJ; Vichinsky E
Hematology Am Soc Hematol Educ Program; 2004; ():14-34. PubMed ID: 15561674
[TBL] [Abstract][Full Text] [Related]
10. A decisional algorithm to start iron chelation in patients with beta thalassemia.
Danjou F; Cabantchik ZI; Origa R; Moi P; Marcias M; Barella S; Defraia E; Dessì C; Foschini ML; Giagu N; Leoni GB; Morittu M; Galanello R
Haematologica; 2014 Mar; 99(3):e38-40. PubMed ID: 24598857
[No Abstract] [Full Text] [Related]
11. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
Saliba AN; El Rassi F; Taher AT
Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
[TBL] [Abstract][Full Text] [Related]
12. Iron-chelating therapy for transfusional iron overload.
Musallam KM; Taher AT
N Engl J Med; 2011 Apr; 364(15):1476; author reply 1477. PubMed ID: 21488787
[No Abstract] [Full Text] [Related]
13. Effectiveness of deferiprone in transfusion-independent beta-thalassemia/HbE patients.
Akrawinthawong K; Chaowalit N; Chatuparisuth T; Siritanaratkul N
Hematology; 2011 Mar; 16(2):113-22. PubMed ID: 21418744
[TBL] [Abstract][Full Text] [Related]
14. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C
Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137
[TBL] [Abstract][Full Text] [Related]
15. Beta-thalassemia.
Rund D; Rachmilewitz E
N Engl J Med; 2005 Sep; 353(11):1135-46. PubMed ID: 16162884
[No Abstract] [Full Text] [Related]
16. Iron Chelation Therapy as a Modality of Management.
Aydinok Y
Hematol Oncol Clin North Am; 2018 Apr; 32(2):261-275. PubMed ID: 29458731
[TBL] [Abstract][Full Text] [Related]
17. Serum ferritin is not a reliable predictor to determine iron overload in thalassemia major patients post-hematopoietic stem cell transplantation.
Jarisch A; Salzmann-Manrique E; Cario H; Grosse R; Soerensen J; Fischer R; Schulz A; Hammerstingl R; Wunderlich A; Bader P
Eur J Haematol; 2018 Dec; 101(6):791-797. PubMed ID: 30187571
[TBL] [Abstract][Full Text] [Related]
18. [Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major].
Gao HY; Li Q; Chen JJ; Chen GF; Li CG
Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jul; 13(7):531-4. PubMed ID: 21752315
[TBL] [Abstract][Full Text] [Related]
19. Thalassemia major: the iron irony.
Stenner RC
Haematologica; 2005 Oct; 90(10):1297A. PubMed ID: 16219550
[No Abstract] [Full Text] [Related]
20. Pharmacokinetics of deferiprone in patients with β-thalassaemia: impact of splenectomy and iron status.
Limenta LM; Jirasomprasert T; Jittangprasert P; Wilairat P; Yamanont P; Chantharaksri U; Fucharoen S; Morales NP
Clin Pharmacokinet; 2011 Jan; 50(1):41-50. PubMed ID: 21028920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
